Shaw L, Poussin M, Rodriguez A, et al. TCRvß-CART Therapy Mediates High Precision Targeting of Malignant T-Cell Clones. Blood Advances. 2022; (doi: 10.1182/bloodadvances.2022008798).
Chimeric antigen receptor T cells (CART) specific to the TCRvß family recognize and kill target cells that express TCRvß, including malignant clones, while minimizing depletion of healthy, non-targeted T cells, new research shows. This capability makes TCRvß-CART immunotherapy a strong candidate as a treatment pathway for peripheral T-cell lymphomas (PTCLs). Potential target antigens for these malignancies are typically expressed by both healthy and cancerous T cells. Existing CART interventions are therefore undermined by fratricide during CAR T-cell expansion and depletion of healthy T cells in vivo, leading to treatment failure and probable patient relapse. The high level of precision with which TCRvß-CARTs wipe out malignant cells, combined with limited fratricide and preservation of immune reactivity, appears to overcome PTCL treatment barriers, according to researchers.